DUBLIN – Rigontec GmbH, a spinout from the University of Bonn in Germany, took in €9.45 million (US$12 million) in a first closing of a series A round to take forward an RNA-based approach to immunotherapy, based on activating retinoic acid inducible protein I (RIG-I), a pathogen-associated molecular pattern that recognizes certain forms of viral RNA.